InnoCare Pharma (HKSE:09969) Debt-to-Revenue : 1.68 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

InnoCare Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,399.3 Mil. InnoCare Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$76.5 Mil. InnoCare Pharma's annualized Revenue for the quarter that ended in Dec. 2023 was HK$880.2 Mil. InnoCare Pharma's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 1.68.

InnoCare Pharma Debt-to-Revenue Historical Data

The historical data trend for InnoCare Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Debt-to-Revenue Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

910.62

860.34

1.22

2.00

1.83

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial											-	1.70	N/A	0.08	1.68

Competitive Comparison of InnoCare Pharma's Debt-to-Revenue

For the Biotechnology subindustry, InnoCare Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCare Pharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Debt-to-Revenue falls into.

InnoCare Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

InnoCare Pharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1399.341	+	76.507)	/	807.796
	=	1.83

InnoCare Pharma's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1399.341	+	76.507)	/	880.164
	=	1.68

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

InnoCare Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (HKSE:09969) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines